Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Amarin Corporation plcNASDAQ: AMRN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $638K fell 12.6% year over year, behind the -1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.6% toward the trailing-twelve-month pace of -1.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.03M USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- +1.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.03M | +0.5% |
| FY2024 | 2024-12-31 | 3.01M | +1.7% |
| FY2023 | 2023-12-31 | 2.97M | -4.2% |
| FY2022 | 2022-12-31 | 3.1M | +8.4% |
| FY2021 | 2021-12-31 | 2.86M | — |
Depreciation & Amortization vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.6% is the 5th highest of 10, against a peer median of -2.6%.
- Depreciation & amortization amounts to 1.4% of revenue for AMRN, versus a peer median of 76.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +2.9% | 28.9% | |
| LTM Mar 2026 | $12.36M USD | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -13.8% | 33645.2% | |
| LTM Mar 2026 | $3.44M USD | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $2.93M USD | -1.6% | -0.7% | 1.4% | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K USD | +79.6% | +28.8% | — |
| LTM Mar 2026 | $605K USD | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
| LTM Mar 2026 | $326K USD | +0.0% | +3.2% | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding AMRN) | — | -2.6% | +3.1% | 76.1% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 583.19M | 369.19M | 306.91M | 228.61M | 213.65M |
| Cost of Revenue | 121.33M | 126.71M | 141.37M | 147.23M | 92.78M |
| Gross Profit | 461.86M | 242.48M | 165.54M | 81.38M | 120.87M |
| Gross Margin | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Research & Development | 29.31M | 30.41M | 22.22M | 20.87M | 19.81M |
| Selling, General & Admin | 408.33M | 304.42M | 199.94M | 152.31M | 115M |
| Operating Expenses | 451.36M | 348.35M | 222.16M | 173.18M | 134.81M |
| Depreciation & Amortization | 2.86M | 3.1M | 2.97M | 3.01M | 3.03M |
| EBITDA | 14.28M | (100.69M) | (50.7M) | (74.18M) | (33.01M) |
| EBITDA Margin | 2.4% | -27.3% | -16.5% | -32.4% | -15.5% |
| Operating Income | 10.5M | (105.87M) | (56.62M) | (91.8M) | (13.94M) |
| Operating Margin | 1.8% | -28.7% | -18.4% | -40.2% | -6.5% |
| Interest Income | 1.22M | 2.82M | 11.86M | 13.4M | 10.85M |
| Interest Expense | 129K | 15K | 8K | 7K | 7K |
| Other Income / Expenses | 789K | 2.06M | 2.95M | 14.6M | (22.11M) |
| Income Before Tax | 11.29M | (103.81M) | (53.67M) | (77.2M) | (36.05M) |
| Pre-Tax Margin | 1.9% | -28.1% | -17.5% | -33.8% | -16.9% |
| Income Tax Expense | 3.56M | 2M | 5.44M | 4.98M | 2.75M |
| Net Income | 7.73M | (105.8M) | (59.11M) | (82.18M) | (38.8M) |
| Net Margin | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (Basic) | 0.39 | (5.20) | (3.00) | (4.00) | (1.80) |
| EPS (Diluted) | 0.38 | (5.20) | (3.00) | (4.00) | (1.80) |
| Weighted Avg Shares | 19.8M | 20.06M | 19.7M | 20.55M | 20.75M |
| Weighted Avg Shares (Diluted) | 20.12M | 20.06M | 20.38M | 20.55M | 20.75M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.